AzTrials
AzTrials

Intubation, IntratrachealPhase 4NCT04872881

Comparison of Effectiveness of Different Airway Management Methods During Percutaneous Tracheostomy

A Phase 4 study testing Endotracheal Tube Insertion, Laryngeal Mask Insertion and Fiberoptic Bronchoscopy in people with Intubation, Intratracheal and Tracheostomy, run by Bozyaka Training and Research Hospital.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Tracheostomy is a vital procedure in the ICU to maintain the airway and prevent complications that may occur due to intubation. It helps reduce the dead space volume, airway resistance and provides comfort to the patients during the weaning from mechanical ventilation. Read more about this study

Who is it for?
Ages 18 to 95 years
What is being tested?
Endotracheal Tube Insertion, Laryngeal Mask Insertion and Fiberoptic Bronchoscopy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
52 participants
Where
No sites listed yet
Study dates
1 May 2021to 1 Oct 2021
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 95 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Non-pregnant patients over 18 years of age
  • Patients who need a tracheostomy
  • Patients whose opening method of tracheostomy is suitable for percutaneous tracheostomy.

Who cannot join

  • Refusal of the procedure by the patient or her legal representative
  • Patients under the age of 18
  • Body mass index> 35 patient group
  • Patients with a mass in the neck region for any reason
  • Skin infection at the procedure site
  • Coagulopathy
  • Inability to palpate the cricoid cartilage

Trial locations and contacts

No sites are listed yet.

About this study

Official title: Comparison of Effectiveness of Different Airway Management Methods During Fiberoptic Bronchoscopy Assisted Percutaneous Tracheostomy

Tracheostomy is a vital procedure in the ICU to maintain the airway and prevent complications that may occur due to intubation. It helps reduce the dead space volume, airway resistance and provides comfort to the patients during the weaning from mechanical ventilation. Two methods are widely used in Percutaneous Dilatational Tracheostomy (PDT): The multiple dilation method (Ciaglia) and the Griggs method.Griggs method will be used in the study.

The Griggs Method: A 10-15 millimeter skin incision is made between the level of the second-third tracheal rings. The location of the needle is confirmed by entering the trachea with an injector filled with 2-3 mL saline from the midline and aspirating air. A J-tipped guidewire is advanced through the needle and the needle is removed. A special forceps with a channel at the tip, through which the guidewire can pass is used in this method. The forceps advanced through the guidewire and then subcutaneous tissues and trachea are dilated in one or two steps. When the stoma is large enough to insert the cannula, it is placed in the trachea and fixed.

Read more

Patients who will undergo tracheostomy in the ICU will be included in the study and randomly assigned into two groups. Two different methods, endotracheal tube (ET) or laryngeal mask (LMA), will be used during the tracheostomy for airway management. In both methods, fiberoptic bronchoscopy will assist the procedure.

Researchers aim to compare the two airway management methods in terms of complications, procedure time, and the number of staff needed.

Read the detailed description

Protection of the airway during percutaneous tracheostomy can be achieved with an endotracheal tube (ETT) or laryngeal mask (LMA).Researchers aimed to compare the use of ETT and LMA in this prospective, randomized study.

Multiple blood gas analyses will be performed during the procedure. Airway failure rates, total procedure time, the occurrence of gastric distension and regurgitation, number of staff needed, complications (Hypercarbia, hypoxia, etc.), and hemodynamic parameters (Non-invasive blood pressure, pulse oximeter, electrocardiogram) will be compared.

Patients will be divided into two groups with simple randomization. A-priori study with 14 patients suggested 52 patients are needed for statistical significance (G*Power 3.1 software was used). Patients will be reviewed for suitability for procedure as stated in the inclusion criteria. Patients and/or relatives will be informed about the study and informed consent will be obtained. Invasive arterial blood pressure monitoring of the patients will be available. Before the procedure, the patients' fasting period for 6 hours will be completed and the nasogastric catheter will be removed. Arterial blood gas sample will be checked before the procedure begins. By placing a transverse elevation under the shoulders, the patients' neck will be extended as appropriate. Patients will be positioned after induction with 2 mg/kg propofol, 0.6 mg/kg rocuronium, and 1 mcg/kg fentanyl IV, and positioning time will be recorded. Propofol infusion at the dose of 6 mg/kg/hour will be started. Electrocautery will be available. Patients will be mechanically ventilated with a controlled mode (CMV) with 7ml/kg tidal volume, 15/min frequency, and 5 cmH2O PEEP. Preoxygenation will be made with 100% FiO2 for 5 minutes.

ETT Group: ETT will be repositioned with direct laryngoscopy (ETT cuff will be inflated just above the vocal cords). "The Reposition Time" will start with the cuff deflation and end with successful ventilation after repositioning. If the ETT can not be repositioned within 5 minutes, it will be considered as a "Failed Airway" and tracheostomy will be continued with the usual method (ETT cuff will be inflated under the vocal cords).

LMA Group: After selecting the appropriate LMA size for the patient, the ET Tube will be removed and the LMA will be inserted. "The LMA Insertion Time" will start with the cuff deflation of the ETT and end with successful ventilation after LMA insertion. If the LMA cannot be inserted in 3 attempts, it will be considered as a "Failed Airway" and tracheostomy will be continued with the usual method (ETT cuff will be inflated under the vocal cords).

After the ventilation is provided, arterial blood gas samples will be analyzed at the 3rd, 6th, and 10th minutes and every 5 minutes afterward until the end of the procedure. In both groups, fiberoptic bronchoscopy will assist the procedure and "Duration of the Confirmation of the Incision Site" will be noted. The bronchoscopy period will start when the physician who will perform the bronchoscope takes the bronchoscope in his hand and ends with the confirmation of the incision site. The area will be cleaned with iodide skin antiseptic, covered with a sterile cover, and surgical tools and tracheostomy kit will be prepared for the procedure. This will be recorded as "Preparation Time". Tracheostomy will preferably be performed between the 2nd and 3rd cartilage rings but one upper or lower level will be used if needed (per patients' anatomy). Local anesthesia will be applied for the incision site with 4 ml of local anesthetic solution containing %2 lidocaine and %0,00125 epinephrine. "Procedure Time" will start with skin incision and end with successful ventilation after the tracheostomy cannula cuff is inflated.

Gastric distension, hypoxia, regurgitation, hemodynamic parameters (every 3 minutes), complications, and the number of staff will be recorded. When the tracheostomy cannula is placed and the patient is ventilated, the procedure will be terminated and confirmed with an anteroposterior chest x-ray.

SPSS (Statistical Package for Social Sciences version 24) was used for statistical calculation. Parametric test results were reported as mean and standard deviation and non-parametric test results as number and percentage or median and interquartile range. The compliance of the data to normal distribution was determined by the single sample Kolmogorov-Smirnov test. Normally distributed quantitative data were compared with the independent sample T-Test, quantitative data that did not follow normal distribution were compared with the Mann-Whitney U test. A Chi-square test was used to compare qualitative data.

The significance level was determined as p <0.05 at the 95% confidence interval for the analyzes.

Being tested
Endotracheal Tube Insertion, Laryngeal Mask Insertion, Fiberoptic Bronchoscopy, Radial Artery Monitoring, Anteroposterior chest x-ray
Keywords
Percutan Dilatational Tracheostomy, Intensive Care Units

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Endotracheal Tube InsertionProcedure or surgery

    ETT will be repositioned with direct laryngoscopy (ETT cuff will be inflated just above the vocal cords)

  • Laryngeal Mask InsertionProcedure or surgery

    After selecting the appropriate LMA size for the patient, the ET Tube will be removed and the LMA will be inserted.

  • Fiberoptic BronchoscopyProcedure or surgery

    After the patients' airway is established, the trachea and the process area will be displayed by the physician.

    The success rate will be increased by performing the procedure with fiberoptic bronchoscopy.

  • Radial Artery MonitoringProcedure or surgery

    The radial artery will be cannulated. Hemodynamic monitoring and blood gas analysis will be done in this way.

  • Anteroposterior chest x-rayDiagnostic test

    When the tracheostomy cannula is placed and the patient is ventilated, the procedure will be terminated and confirmed with anteroposterior chest x-ray.

  • Arterial Blood Gas AnalysesDiagnostic test

    Hypoxia, acidosis and carbon dioxide increase will be followed

  • Propofol FreseniusDrug

    2mg/kg of propofol 2% injectable solution was given and propofol infusion at the dose of 6 mg/kg/hour will be started.

  • RocuroniumDrug

    Also called Muscuron

    0.6 mg/kg of rocuronium 50mg/5ml injectable solution was given.

  • FentanylDrug

    1mcg/kg fentanyl of 0.5 mg/10ml injectable solution was given.

Study groups in NCT04872881
Study groupRoleWhat they receive
ETT GroupActive comparatorETT will be repositioned with direct laryngoscopy (ETT cuff will be inflated just above the vocal cords). "The Reposition Time" will start with the cuff deflation and end with successful ventilation after repositioning. If the ETT can not be repositioned within 5 minutes, it will be considered as a "Failed Airway" and tracheostomy will be continued with the usual method (ETT cuff will be inflated under the vocal cords)
Receives: Procedure: Endotracheal Tube Insertion; Procedure: Fiberoptic Bronchoscopy; Procedure: Radial Artery Monitoring; Diagnostic Test: Anteroposterior chest x-ray; Diagnostic Test: Arterial Blood Gas Analyses; Drug: Propofol Fresenius; Drug: Rocuronium; Drug: Fentanyl
LMA GroupActive comparatorAfter selecting the appropriate LMA size for the patient, the ET Tube will be removed and the LMA will be inserted. "The LMA Insertion Time" will start with the cuff deflation of the ETT and end with successful ventilation after LMA insertion. If the LMA cannot be inserted in 3 attempts, it will be considered as a "Failed Airway" and tracheostomy will be continued with the usual method (ETT cuff will be inflated under the vocal cords)
Receives: Procedure: Laryngeal Mask Insertion; Procedure: Fiberoptic Bronchoscopy; Procedure: Radial Artery Monitoring; Diagnostic Test: Anteroposterior chest x-ray; Diagnostic Test: Arterial Blood Gas Analyses; Drug: Propofol Fresenius; Drug: Rocuronium; Drug: Fentanyl

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Arterial Blood Gas Analysis

    Monitoring of hypoxia, acidosis, and carbon dioxide

    Measured: Before the procedure

  2. Arterial Blood Gas Analysis

    Monitoring of hypoxia, acidosis, and carbon dioxide

    Measured: 3rd minute after ventilation

  3. Arterial Blood Gas Analysis

    Monitoring of hypoxia, acidosis, and carbon dioxide

    Measured: 6th minute after ventilation

  4. Arterial Blood Gas Analysis

    Monitoring of hypoxia, acidosis, and carbon dioxide

    Measured: 10th minute after ventilation

  5. Arterial Blood Gas Analysis

    Monitoring of hypoxia, acidosis, and carbon dioxide

    Measured: When the tracheostomy cannula cuff is inflated

  6. Positioning time

    By placing a transverse elevation under the shoulders, the patients' neck will be extended as approprite.

    Measured: Before the procedure

  7. The Reposition Time

    The Reposition Time will start with the cuff deflation and end with successful ventilation after repositioning. If the ETT can not be repositioned within 5 minutes, it will be considered as a "Failed Airway".

    Measured: Before the procedure

  8. The LMA Insertion Time

    The LMA Insertion Time will start with the cuff deflation of the ETT and end with successful ventilation after LMA insertion. If the LMA cannot be inserted in 3 attempts, it will be considered as a "Failed Airway"

    Measured: Before the procedure

  9. Duration of the Confirmation of the Incision Site

    The bronchoscopy period will start when the physician who will perform the bronchoscope takes the bronchoscope in his hand and ends with the confirmation of the incision site

    Measured: Before the procedure

  10. Preparation Time

    Area will be cleaned with iodide skin antiseptic, covered with a sterile cover and surgical tools and tracheostomy kit will be prepared for the procedure

    Measured: Before the procedure

  11. Procedure Time

    "Procedure Time" will start with skin incision and end with successful ventilation after tracheostomy cannula cuff is inflated.

    Measured: 15 minutes after the procedure begins

Secondary outcomes (7)
  1. Incidence of gastric distension

    Measured: Throughout the tracheostomy procedure

  2. Incidence of hypoxia

    Measured: Throughout the tracheostomy procedure

  3. Incidence of regurgitation

    Measured: Throughout the tracheostomy procedure

  4. The number of staff needed

    Measured: Throughout the tracheostomy procedure

  5. Heart rate

    Measured: Every 3 minutes during the procedure

  6. Blood pressure

    Measured: Every 3 minutes during the procedure

  7. Pulse oximeter

    Measured: Every 3 minutes during the procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 May 2021
  2. Study start1 May 2021 (estimated)
  3. Primary completion1 Aug 2021 (estimated)
  4. Study completion1 Oct 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
There are two groups: ETT Group and LMA Group
Masking
None (open label)
Enrolment
52 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04872881
Sponsor's protocol ID
eliftez
Status last verified
Apr 2021
First submitted
22 Apr 2021
Last updated
5 May 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Endotracheal Tube Insertion, Laryngeal Mask Insertion and Fiberoptic Bronchoscopy in people with Intubation, Intratracheal and Tracheostomy, run by Bozyaka Training and Research Hospital.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 5 May 2021. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Elif Göktaş (05062073485, e.goktas44@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Arterial Blood Gas Analysis (time frame: Before the procedure). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 May 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in